Podcast
Medscape InDiscussion: Breast Cancer and HER2
Hosted by Medscape · EN
Listen to Medscape InDiscussion: Breast Cancer and HER2, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001124. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
12episodes
Episodes
Newest firstAll episodes
S2 Episode 6: Beyond pCR Rates in Breast Cancer and HER2: Understanding Response, Residual Disease, and Outcomes
Mar 2400:23:22Tap to summarizeDrs Kathy Miller and Lajos Pusztai discuss predicting which patients will have a PCR, and the impact this has on new treatments or reducing the intensity of treatments. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002987. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview Overall Survival With Pembrolizumab in Early-Stage Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/39282906/ I-SPY 2: A Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33312344/ Treatment Efficacy Score-Continuous Residual Cancer Burden-Based Metric to Compare Neoadjuvant Chemotherapy Efficacy Between Randomized Trial Arms in Breast Cancer Trials https://pubmed.ncbi.nlm.nih.gov/35513244/ Predictors of Pathological Complete Response to Neoadjuvant Treatment and Changes to Post-Neoadjuvant HER2 Status in HER2-Positive Invasive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33526875/ Clinical Decision Impact of HER2DX, an Algorithm-Powered Genomic Diagnostic in Early-Stage HER2-Positive Breast Cancer: Results From a Prospective Real-World Study https://www.sciencedirect.com/science/article/pii/S2949820125000128 Predictive Value of Tumor-Infiltrating Lymphocytes for Neoadjuvant Therapy Response and Prognosis in Breast Cancer: A Multicenter Retrospective Study Based on Chinese Population https://pubmed.ncbi.nlm.nih.gov/41094431/ Predicting Pathologic Complete Response (pCR) From Clinicopathologic Variables and HER2DX Genomic Test in Stage II/III HER2+ Breast Cancer Treated With Taxane, Trastuzumab, and Pertuzumab (THP): Secondary Results From the EA1181/CompassHER2 pCR Trial https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.501 MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer: FLEX Registry Real-World Data https://pubmed.ncbi.nlm.nih.gov/40796181/ Oncotype DX Breast Recurrence Score®: A Review of Its Use in Early-Stage Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32613290/ Toll-like Receptor-Based Strategies for Cancer Immunotherapy https://pubmed.ncbi.nlm.nih.gov/34124272/ The Tale of TILs in Breast Cancer: A Report From The International Immuno-Oncology Biomarker Working Group https://pubmed.ncbi.nlm.nih.gov/34853355/
Transcribe →S2 Episode 5: HER2 Positive, Low, Ultralow: What Testing Means in the ADC Era
Feb 2400:22:51Tap to summarizeDrs Kathy Miller and Sunil Badve discuss how HER2 testing has evolved over time as the need for that clinical testing has shifted, including assay limits, biology, and clinical impact. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002986. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview Standardized Pathology Report for HER2 Testing in Compliance With 2023 ASCO/CAP Updates and 2023 ESMO Consensus Statements on HER2-Low Breast Cancer https://pubmed.ncbi.nlm.nih.gov/37770765/ Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update https://pubmed.ncbi.nlm.nih.gov/37284804/ Human Breast Cancer: Correlation of Relapse and Survival With Amplification of the HER-2/neu Oncogene https://pubmed.ncbi.nlm.nih.gov/3798106/ Inhibition of Tumor Growth by a Monoclonal Antibody Reactive With an Oncogene-Encoded Tumor Antigen https://pubmed.ncbi.nlm.nih.gov/3466178/ HercepTest https://www.accessdata.fda.gov/cdrh_docs/pdf/P980018S010b.pdf Effective Extracellular Payload Release and Immunomodulatory Interactions Govern the Therapeutic Effect of Trastuzumab Deruxtecan (T-DXd) https://pubmed.ncbi.nlm.nih.gov/40175391/ Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients With HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience https://pubmed.ncbi.nlm.nih.gov/35008143/ Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies https://pubmed.ncbi.nlm.nih.gov/38471052/ Evidence Accumulates Against Sequencing Topo1-ADCs in HER2-Low Metastatic Breast Cancers: Results From International, Retrospective, Real-world ADC-Low-Europe Cohort https://sabcs.multilearning.com/sabcs/2025/eposters/4192135/francois.poumeaud.evidence.accumulates.against.sequencing.topo1-adcs.in.html Reversal of Tamoxifen Resistant Breast Cancer by Low Dose Estrogen Therapy https://pubmed.ncbi.nlm.nih.gov/15860267/
Transcribe →S2 Episode 4: ILD and ADCs in the Treatment of Breast Cancer and HER2: Early Symptoms, Pulmonary Collaboration, and Ongoing Vigilance
Jan 2200:21:37Tap to summarizeDrs Kathy Miller and Erika Hamilton discuss ILD linked to ADCs, highlighting early symptoms, key CT findings, pulmonary collaboration, steroid management, and ongoing vigilance. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002985. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview Diagnosis and Management of Drug-Induced Interstitial Lung Disease in the Context of Anti-Cancer Therapy: A Multidisciplinary Viewpoint by Portuguese Experts https://pubmed.ncbi.nlm.nih.gov/39500817/ Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/37207306/ Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies https://pubmed.ncbi.nlm.nih.gov/39524467/ A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34226162/ Detecting and Managing T-DXd-Related Interstitial Lung Disease: The Five "S" Rules https://pubmed.ncbi.nlm.nih.gov/37207309/ Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights From an Asia-Pacific Multidisciplinary Panel https://pubmed.ncbi.nlm.nih.gov/37552439/ Neoadjuvant Trastuzumab Deruxtecan Alone or Followed by Paclitaxel, Trastuzumab, and Pertuzumab for High-Risk HER2-Positive Early Breast Cancer (DESTINY-Breast11): A Randomised, Open-Label, Multicentre, Phase III Trial https://pubmed.ncbi.nlm.nih.gov/41130363/ Geyer CE Jr, Park YH, Shao Z, et al; On behalf of the DESTINY-Breast05 investigators. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05. Presented at: ESMO Congress 2025; October 17-21, 2025; Berlin, Germany https://datasourcebydaiichisankyo.com/documents/d/datahub/lba1_geyer_destiny-breast05-interim-analysis_esmo-2025_oral-presentation_final Evaluating Risk Factors for Trastuzumab-Deruxtecan Pneumonitis in Patients With Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/39901280/ CPIC (Clinical Pharmacogenetics Implementation Consortium) https://cpicpgx.org/ Lymphangitic Carcinomatosis https://www.ncbi.nlm.nih.gov/books/NBK560921/
Transcribe →S2 Episode 3: Recent Changes in the Management of Metastatic HER2-Positive Breast Cancer
Dec 1800:22:20Tap to summarizeDrs Kathy Miller and Sara Tolaney discuss changes in the management of first-line metastatic HER2-positive disease and the DESTINY-Breast09 trial results. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002984. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview DESTINY-Breast09, New Breakthroughs in First-Line Therapy for HER2-Positive Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/40756960/ Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA): End-of-Study Results From a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Study https://pubmed.ncbi.nlm.nih.gov/32171426/ Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis https://pubmed.ncbi.nlm.nih.gov/36716289/ Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results From MARIANNE https://pubmed.ncbi.nlm.nih.gov/31318460/ Real-World Data on Trastuzumab Emtansine (TDM1) Efficacy and Safety: Results of a Single-Centre Retrospective Study of HER2-Positive Metastatic Breast Cancer Patients https://pubmed.ncbi.nlm.nih.gov/40437155/ Trastuzumab Deruxtecan (T-DXd) + Pertuzumab (P) vs Taxane + Trastuzumab + Pertuzumab (THP) for First-Line (1L) Treatment of Patients (pts) With Human Epidermal Growth Factor Receptor 2–Positive (HER2+) Advanced/Metastatic Breast Cancer (a/mBC): Interim Results From DESTINY-Breast09 https://meetings.asco.org/abstracts-presentations/253126 Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA) https://www.clinicaltrials.gov/study/NCT02947685 Trastuzumab Deruxtecan Versus Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer: Long-Term Survival Analysis of the DESTINY-Breast03 Trial https://pubmed.ncbi.nlm.nih.gov/38825627/ PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer (DEMETHER) https://www.clinicaltrials.gov/study/NCT06172127 A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-Risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) https://www.clinicaltrials.gov/study/NCT04622319 Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-Positive Early Breast Cancer https://clinicaltrials.gov/study/NCT05113251
Transcribe →S2 Episode 2: Addressing Common Toxicities for Breast Cancer HER2-Targeted Therapies
Nov 2500:24:42Tap to summarizeDrs Kathy Miller and Alexandra Thomas discuss important toxicities for breast cancer HER2-targeted therapies and how to improve the patient experience. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002982. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview Polyhydramnios and Oligohydramnios https://emedicine.medscape.com/article/975821-overview Management of Diarrhea in Patients With HER2-Positive Breast Cancer Treated With Neratinib: A Case Series and Summary of The Literature https://pubmed.ncbi.nlm.nih.gov/34800263/ Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients https://pubmed.ncbi.nlm.nih.gov/37163123/ The Comparative Efficacy and Risk of Harms of the Intravenous and Subcutaneous Formulations of Trastuzumab in Patients With HER2-Positive Breast Cancer: A Rapid Review https://pubmed.ncbi.nlm.nih.gov/31829250/ Overview of Antibody-Drug Conjugates Nonclinical and Clinical Toxicities and Related Contributing Factors https://pubmed.ncbi.nlm.nih.gov/40491603/ Toxicity Profile of Antibody-Drug Conjugates in Breast Cancer: Practical Considerations https://pubmed.ncbi.nlm.nih.gov/37554126/ Oral Mucositis Associated With Antibody-Drug Conjugates in Gynecologic Oncology: Strategies for Prevention and Treatment https://pubmed.ncbi.nlm.nih.gov/40712557/ Incidence of Antibody-Drug Conjugate-Related Hepatotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/39703774/ T-DM1-Induced Thrombocytopenia in Breast Cancer Patients: New Perspectives https://pubmed.ncbi.nlm.nih.gov/32570117/ Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/36454580/ Lung Toxicity Induced by Anti-HER2 Antibody-Drug Conjugates for Breast Cancer https://pubmed.ncbi.nlm.nih.gov/38295890/
Transcribe →S2 Episode 1: Cardiac Toxicity and HER2-Targeted Therapy: Who's at Risk?
Nov 2500:22:54Tap to summarizeDrs Kathy Miller and Bonnie Ky discuss cardiovascular concerns with HER2-targeted therapies and how to work with cardiology colleagues for the best treatment outcomes. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002981. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview Risk of Trastuzumab-Related Cardiotoxicity in Early Breast Cancer Patients: A Prospective Observational Study https://pubmed.ncbi.nlm.nih.gov/25548585/ MUGA Scan https://www.ncbi.nlm.nih.gov/books/NBK564365/ Myocardial Strain Imaging: Theory, Current Practice, and the Future https://pubmed.ncbi.nlm.nih.gov/39269417/ Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer: Final 10-Year Analysis of the Open-Label, Single-Arm, Phase 2 APT Trial https://pubmed.ncbi.nlm.nih.gov/36858723/ Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance https://pubmed.ncbi.nlm.nih.gov/40246379/ Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy https://pubmed.ncbi.nlm.nih.gov/40537192/ Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology https://pubmed.ncbi.nlm.nih.gov/36213359/ Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity https://pubmed.ncbi.nlm.nih.gov/36612307/ Prospective Evaluation of the Cardiac Safety of HER2-Targeted Therapies in Patients With HER2-Positive Breast Cancer and Compromised Heart Function: The SAFE-HEaRt Study https://pubmed.ncbi.nlm.nih.gov/30852761/ Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial https://pubmed.ncbi.nlm.nih.gov/34396157/
Transcribe →S1 Episode 6: New Classification of HER2–Ultra-Low Breast Cancer: What Do We Need to Know?
Dec 19, 202400:17:20Tap to summarizeDrs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2–ultra-low breast cancer. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001338. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview Prevalence of "HER2 Ultra-Low" Among Patients With Advanced Breast Cancer With Historical IHC0 Status https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e13156 Targeting HER2-Positive Breast Cancer: Advances and Future Directions https://pubmed.ncbi.nlm.nih.gov/36344672/ Are There More HER2 FISH in the Sea? An Institution's Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients With HER2 Negative Immunohistochemistry https://pubmed.ncbi.nlm.nih.gov/37936021/ Trastuzumab Deruxtecan (T-DXd) vs Physician's Choice of Chemotherapy (TPC) in Patients (Pts) With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low or HER2-Ultralow Metastatic Breast Cancer (MBC) With Prior Endocrine Therapy (ET): Primary Results From DESTINY-Breast06 (DB-06) https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA1000 The American Society of Clinical Oncology-College of American Pathologists Guideline Update for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer https://pubmed.ncbi.nlm.nih.gov/37303241/ Prognostic Relevance of the HER2 Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients Screened for Participation in the DETECT Study Program https://pubmed.ncbi.nlm.nih.gov/34839105/ Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update https://pubmed.ncbi.nlm.nih.gov/31928404/ Adjuvant Therapy for Breast Cancer https://emedicine.medscape.com/article/1946040-overview Tumor Infiltrating Lymphocytes (TILs) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications From Pathologist's Perspective https://pubmed.ncbi.nlm.nih.gov/37760449/
Transcribe →S1 Episode 5: Shared Decision-Making in Sequencing ADCs for HER2-Low Breast Cancer
Nov 21, 202400:24:27Tap to summarizeKathy D. Miller, MD, and Stephanie L. Graff, MD, discuss sequencing of ADCs for metastatic HER2-low breast cancer including sequencing, toxicities, and clinical trials. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001337. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions https://pubmed.ncbi.nlm.nih.gov/37762027/ Pathological Identification of HER2-Low Breast Cancer: Tips, Tricks, and Troubleshooting for the Optimal Test https://pubmed.ncbi.nlm.nih.gov/37077201/ Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35665782/ Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) https://pubmed.ncbi.nlm.nih.gov/32954927/ Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles https://pubmed.ncbi.nlm.nih.gov/38132377/ Subtypes of Breast Cancer https://www.ncbi.nlm.nih.gov/books/NBK583808/ Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/ Trastuzumab Deruxtecan in Metastatic Breast Cancer With Variable HER2 Expression: The Phase 2 DAISY Trial https://pubmed.ncbi.nlm.nih.gov/37488289/ Decoding TROP2 in Breast Cancer: Significance, Clinical Implications, and Therapeutic Advancements https://pubmed.ncbi.nlm.nih.gov/37954074/ TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd (TRADE DXd) https://clinicaltrials.gov/study/NCT06533826
Transcribe →S1 Episode 4: Managing Central Nervous System Metastasis in Patients With HER2-Positive Breast Cancer
Oct 22, 202400:26:00Tap to summarizeDrs Kathy Miller and Nancy U. Lin discuss central nervous system involvement in HER2-positive breast cancer, including the biology and management of patients. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001336. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies https://pubmed.ncbi.nlm.nih.gov/34208287/ Adjuvant Trastuzumab Emtansine in HER2-Positive Breast Cancer Patients With HER2-Negative Residual Invasive Disease in KATHERINE https://pubmed.ncbi.nlm.nih.gov/36117201/ Raising the Bar for Real-World Data in Oncology: Approaches to Quality Across Multiple Dimensions https://pubmed.ncbi.nlm.nih.gov/38241599/ Anti-Angiogenic Therapy: Current Challenges and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/33916438/ ALK-Positive Lung Cancer: A Moving Target https://pubmed.ncbi.nlm.nih.gov/36797503/ Radiotherapy for HER 2 Positive Brain Metastases: Urgent Need for a Paradigm Shift https://pubmed.ncbi.nlm.nih.gov/35326665/ Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies https://pubmed.ncbi.nlm.nih.gov/38471052/ Stereotactic Radiosurgery and Local Control of Brain Metastases From Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/36433878/ Multi-institutional Validation of Brain Metastasis Velocity, a Recently Defined Predictor of Outcomes Following Stereotactic Radiosurgery https://pubmed.ncbi.nlm.nih.gov/31526671/ Hippocampal Avoidance Whole Brain Radiotherapy in Brain Metastasis Using Volumetric Modulated Arc Therapy: Experience From a Regional Cancer Centre of Eastern India https://pubmed.ncbi.nlm.nih.gov/37795235/ Leptomeningeal Metastases https://emedicine.medscape.com/article/1156338-overview Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis https://pubmed.ncbi.nlm.nih.gov/35802849/ A Phase I/II Study of Intrathecal Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive (HER2-Positive) Cancer With Leptomeningeal Metastases: Safety, Efficacy, and Cerebrospinal Fluid Pharmacokinetics https://pubmed.ncbi.nlm.nih.gov/35948282/ Tucatinib-Trastuzumab-Capecitabine for Treatment of Leptomeningeal Metastasis in HER2+ Breast Cancer: TBCRC049 Phase 2 Study Results https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2018 Radiological Response of Leptomeningeal Metastases According to Revised RANO Criteria Is Associated With Overall Survival in Breast Cancer Patients https://pubmed.ncbi.nlm.nih.gov/37243480/
Transcribe →S1 Episode 3: Evolving Conversations in HER2+ Oligometastatic Breast Cancer Management
Sep 19, 202400:21:54Tap to summarizeDrs Kathy D. Miller and Heather A. Parsons explore the complexities and evolving strategies in managing HER2+ oligometastatic breast cancer, tackling curative intent, treatment duration, and the promise of emerging biomarkers. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001335. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview De Novo Oligometastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/37607325/ A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/30233772/ Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) https://pubmed.ncbi.nlm.nih.gov/34995128/ Stereotactic Body Radiation Therapy for Oligometastatic Breast Cancer: A Retrospective Multicenter Study https://pubmed.ncbi.nlm.nih.gov/34778049/ NRG-BR002: A Phase IIR/III Trial of Standard of Care Systemic Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Resection (SR) for Newly Oligometastatic Breast Cancer (NCT02364557) https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.1007 Systemic Therapies for HER2-Positive Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/38201451/ Oligometastatic Breast Cancer and Metastasis-Directed Treatment: An Aggressive Multimodal Approach to Reach the Cure https://pubmed.ncbi.nlm.nih.gov/36950272/ Circulating Tumor Biomarkers in Early-Stage Breast Cancer: Characteristics, Detection, and Clinical Developments https://pubmed.ncbi.nlm.nih.gov/37941557/ Minimal Residual Disease (MRD) Detection in Solid Tumors Using Circulating Tumor DNA: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/37636270/
Transcribe →